A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

April 30, 2018

Conditions
Bladder Cancer
Interventions
BIOLOGICAL

HS-410

Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96

BIOLOGICAL

Placebo

Injection containing sterile solution but no cells

BIOLOGICAL

BCG

Vaccine derived from a live bacterium

Trial Locations (19)

10471

Montefiore Medical Center, The Bronx

19107

Thomas Jefferson University, Philadelphia

21287

Johns Hopkins University, Baltimore

23462

Urology of Virginia, Virginia Beach

27599

University of North Carolina Chapel Hill, Chapel Hill

29572

Carolina Urologic Research Center, Myrtle Beach

47130

First Urology, Jeffersonville

47905

Horizon Oncology Research, Lafayette

55455

University of Minnesota, Minneapolis

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

66205

University of Kansas Cancer Center, Westwood

75231

Urology of North Texas, Dallas

77030

MD Anderson Cancer Center, Houston

80211

Urology Center of Colorado, Denver

90095

University of California at Los Angeles, Los Angeles

90505

Skyline Urology, Torrance

91411

Skyline Urology, Sherman Oaks

01655

University of Massachusetts, Worcester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Heat Biologics

INDUSTRY